Real-world effectiveness of novel hormonal agents and docetaxel in patients with prostate cancer: A head-to-head comparison.

Although NHAs showed relatively lower 50% PSA response rates across all subgroups, the differences did not reach statistical significance ( Table 1 ).

also in 111,027 other papers